Evidence map›Paper›PMID 32303278›Full record

ReviewSeminars in nephrology2020

The Role of Circulating Cell-Free Hemoglobin in Sepsis-Associated Acute Kidney Injury.

V Eric Kerchberger, Lorraine B Ware

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Aging Kidney and Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Research progress on the pathogenesis of AKI complicated by ECMO.Clinical and experimental nephrology · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

V Eric KerchbergerDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN.
Lorraine B WareDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville TN. Electronic address: lorraine.ware@vumc.org.
Vanderbilt University Medical Center · US

Funding

Vanderbilt Biomedical Informatics Training ProgramT15LM007450 · NLM · VANDERBILT UNIVERSITY · PI Jessica S. Ancker, Bradley A. Malin · 2002 to 2026
$19.7M
Targeting cell-free hemoglobin in sepsis to reduce lung microvascular permeability: mechanistic and translational studiesR01HL135849 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BASTARACHE, JULIE ANNE, WARE, LORRAINE B · 2017 to 2020
$2.2M
Midcareer Investigator Award in Patient-Oriented Research in Acute Lung InjuryK24HL103836 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WARE, LORRAINE B · 2010 to 2020
$1.6M
NHLBI NIH HHS K24 HL103836NHLBI NIH HHS R01 HL135849NLM NIH HHS T15 LM007450
6 · The paper itself

Abstract

Sepsis is a heterogeneous clinical syndrome that is complicated commonly by acute kidney injury (sepsis-AKI). Currently, no approved pharmacologic therapies exist to either prevent sepsis-AKI or to treat sepsis-AKI once it occurs. A growing body of evidence supports a connection between red blood cell biology and sepsis-AKI. Increased levels of circulating cell-free hemoglobin (CFH) released from red blood cells during hemolysis are common during sepsis and can contribute to sepsis-AKI through several mechanisms including tubular obstruction, nitric oxide depletion, oxidative injury, and proinflammatory signaling. A number of potential pharmacologic therapies targeting CFH in sepsis have been identified including haptoglobin, hemopexin, and acetaminophen, and early phase clinical trials have suggested that acetaminophen may have beneficial effects on lipid peroxidation and kidney function in patients with sepsis. Bedside measurement of CFH levels may facilitate predictive enrichment for future clinical trials of CFH-targeted therapeutics. However, rapid and reliable bedside tests for plasma CFH will be required for such trials to move forward.

Indexed as

AcetaminophenAcute Kidney InjuryAnemia, Sickle CellAnimalsCoronary Artery BypassDisseminated Intravascular CoagulationEryptosisErythrocyte DeformabilityHaptoglobinsHemeHemoglobinsHemolysisHemopexinHumansKidney TubulesMalariaAcetaminophenHaptoglobinsHemeHemoglobinsHemopexinNitric OxideReactive Oxygen Speciesacetaminophenacute kidney injurybiomarkerscell-free hemoglobinhemolysisSepsis

Identifiers

PMID32303278
PMCPMC7172012
OpenAlexW3016576290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.